Revenue Performance - Total revenue for the six months ended March 31, 2024, was HK92.109million,comparedtoHK107.635 million in the same period last year[32] - Revenue from foundation and site formation works decreased to HK24.349millionfromHK54.988 million year-over-year[32] - Revenue from other construction works increased significantly to HK32.508millionfromHK12.324 million in the previous year[32] - Sales of health products generated HK17.034millioninrevenue,downfromHK19.760 million in the prior year[32] - Revenue decreased by 14.4% to HK92.1millioninthesixmonthsendedMarch31,2024,comparedtoHK107.6 million in the same period last year[68] - Revenue from foundation and site formation works decreased to HKD 24.349 million (26.4% of total revenue) in 2024 from HKD 54.988 million (51.1% of total revenue) in 2023[85] - Revenue from the health management and consulting business decreased from HKD 19.8 million for the six months ended March 31, 2023, to HKD 17.0 million for the six months ended March 31, 2024[131] - The company's total revenue for the six months ended March 31, 2024, was HKD 92.109 million, compared to HKD 107.635 million for the same period in 2023[142] Profit and Loss - Gross profit decreased by 6.4% to HK17.6million,withgrossmarginimprovingto19.215.6 million from HK9.8millioninthepriorperiod[50]−Netlossattributabletothecompany′sownersincreasedtoHK16.9 million from HK10.5million[52]−Basicanddilutedlosspershareincreasedto2.11HKcentsfrom1.31HKcents[53]−Thegroup′sgrossprofitmarginforgeneralconstructionandrelatedservicesturnedfromagrosslossmarginof81.0127.044 million from HK158.651millionasofSeptember30,2023[12]−NetcurrentassetsstoodatHK8.644 million, a decrease from HK26.970millionattheendofthepreviousfiscalperiod[12]−Totalequityattributabletothecompany′sownerswasHK45.664 million, with non-controlling interests at HK(2.493)million[4]−Thecompany′stotalassetslesscurrentliabilitieswereHK31.660 million, down from HK49.614millionasofSeptember30,2023[12]−TotalassetsdecreasedtoHK153.4 million from HK201.8millionasofMarch31,2024[54]−Thegroup′snon−currentassetsinChinaincreasedtoHKD18.062millionin2024fromHKD16.327millionin2023,whileassetsinHongKongdecreasedtoHKD4.954millionfromHKD6.317million[91]−Thegroup′sbankcashandbalancesdecreasedtoHKD29.687millionin2024fromHKD41.450millionin2023[103]−TradereceivablesoverdueasofMarch31,2024,amountedtoHKD11.231million,withHKD2.260millionoverduefor90daysormore[102]−Thegroupacquiredproperty,plant,andequipmentworthHKD813,000in2024,comparedtoHKD506,000in2023[98]−Tradereceivablesdecreasedfrom25,006to18,985thousandHKD,withaslightreductioninimpairmentlossprovisionfrom4,400to4,431thousandHKD[125]−Tradepayablesdecreasedsignificantlyfrom9,099to3,573thousandHKD,indicatingimprovedpaymenttermsorreducedliabilities[121]−AsofMarch31,2024,thecompany′snetcurrentassetswereHKD8.6million,downfromHKD27.0millionasofSeptember30,2023[152]−Thecompany′sbankbalancesandcashstoodatHKD29.7millionasofMarch31,2024,comparedtoHKD41.5millionasofSeptember30,2023[152]−Thecompany′stotalequityattributabletoownerswasHKD28.7millionasofMarch31,2024,downfromHKD45.7millionasofSeptember30,2023[152]−Thecompany′stotaldebt,includingbankborrowingsandleaseliabilities,wasHKD34.7millionasofMarch31,2024,comparedtoHKD50.5millionasofSeptember30,2023[152]−ThecompanyhasavailablebankfinancingofHKD9.0millionasofMarch31,2024,withnoneutilizedasofSeptember30,2023[152]−ThecompanyhaspledgedvehicleswithanetbookvalueofHKD0.9millionascollateralunderirrevocableleaseagreementsasofMarch31,2024,upfromHKD0.5millionasofSeptember30,2023[154]−Thecompany′scapital−to−debtratioincreasedto131.7(35.577) million[37] - Administrative and other operating expenses remained stable at approximately HKD 35.9 million in 2023 and HKD 35.6 million in 2024[78] - Employee benefits expenses, including directors' remuneration, surged from 16,151 to 24,234 thousand HKD, indicating higher labor costs[112] - R&D costs decreased from 5,525 to 3,046 thousand HKD, suggesting a reduction in innovation spending[112] - Total employee costs for the six months ended March 31, 2024, were approximately HKD 24.2 million, compared to HKD 18.0 million in the same period last year[184] Other Income and Losses - Other income, gains, and losses amounted to HK2.137million,asignificantdropfromHK7.471 million in the same period last year[33] - Other income, gains, and losses decreased by HKD 5.4 million from HKD 7.5 million in 2023 to HKD 2.1 million in 2024, primarily due to reduced agency commission income and the absence of a one-time legal claim compensation received in 2023[77] - The group recorded a tax expense of HKD 37,000 in 2024, compared to HKD 14,000 in 2023, mainly due to taxable profits from the China business[80] Projects and Operations - The company increased capital in two subsidiaries, Baocheng Construction Limited and Huang'an Construction Limited[67][71] - Revenue decline was primarily due to reduced projects in foundation and site formation works, general building works, and construction-related consultancy services[74] - Health management and consulting business revenue decreased due to lower sales of health intelligent robots[74] - The company has several ongoing projects with expected completion dates ranging from 2024 to 2025, indicating a robust project pipeline[123][124] - The company had 24 ongoing construction projects as of March 31, 2024, with a total contract value of HKD 203.6 million, compared to 23 projects with a total contract value of HKD 341.4 million as of September 30, 2023[129] - The company's subsidiary, Huang An Construction Limited, is involved in a dispute with a school in Hong Kong over unpaid fees for design and construction work, with arbitration proceedings ongoing[163] Financial Reporting and Compliance - The company applied new and revised Hong Kong Financial Reporting Standards during the period, including amendments to HKFRS 10 and HKAS 28[59] - The company has maintained full compliance with the Corporate Governance Code as of March 31, 2024[191] - The Audit Committee, established on September 17, 2018, reviewed the unaudited condensed consolidated financial statements for the six months ended March 31, 2024[193] - The company's board of directors includes executive directors and independent non-executive directors as of the announcement date[194] Capital and Financing - The company has utilized HKD 86.1 million of the net proceeds from its IPO as of March 31, 2024, with the remaining HKD 0.5 million expected to be fully utilized by September 30, 2024[151] - The company's net proceeds from the IPO amounted to approximately HKD 86.6 million, which have been partially utilized according to the future plans and uses of proceeds as disclosed in the prospectus[158] - The company's capital structure consists solely of ordinary shares, with no changes since its listing on the Hong Kong Stock Exchange on October 16, 2018[160] - The company has no capital commitments as of March 31, 2024, compared to none as of September 30, 2023[165] - The company's operating and investment activities are primarily funded by cash generated from operations, bank borrowings, and equity from shareholders[161] - The company has no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the six months ended March 31, 2024[178] Share Options and Employee Incentives - The company has adopted a share option plan to attract and retain qualified personnel, offering additional incentives to employees, directors, consultants, and other stakeholders[173] - The company's share option plan allows for the issuance of shares up to 10% of the total issued shares at the time of plan approval, with the limit renewable every three years[188] - The share option plan, effective from September 17, 2018, for a ten-year period, had 80,000,000 options available for grant as of March 31, 2024[200] - No share options were granted, exercised, expired, lapsed, or canceled during the six months ended March 31, 2024[200] - The company's share option plan requires shareholder approval for any grants exceeding 1% of the issued shares within any 12-month period[198] Legal and Governance Issues - The company has suspended the duties and powers of an executive director, Mr. Sun Wei, due to his alleged involvement in a potential financial fraud case under investigation in China[181][182] - The company did not buy back or redeem any of its listed securities during the six months ended March 31, 2024[185] - The company has no interim dividend declared or proposed for the six months ended March 31, 2024, consistent with the same period in 2023[169] Employee and Labor Costs - The company had 210 employees as of March 31, 2024, an increase from 172 employees in the same period last year, primarily due to recruitment for the development of health management and consulting business in China[184]